Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.

Autor: Styczynski J; Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Torun, Bydgoszcz, Poland. jstyczynski@cm.umk.pl., Tridello G; Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.; EBMT Leiden Study Unit, Leiden, The Netherlands., Koster L; EBMT Leiden Study Unit, Leiden, The Netherlands., Knelange N; EBMT Leiden Study Unit, Leiden, The Netherlands., Wendel L; EBMT Leiden Study Unit, Leiden, The Netherlands., van Biezen A; EBMT Leiden Study Unit, Leiden, The Netherlands., van der Werf S; EBMT Leiden Study Unit, Leiden, The Netherlands., Mikulska M; Division of Infectious Diseases, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, Genoa, Italy., Gil L; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland., Cordonnier C; Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris (AP-HP) and Paris-Est-Créteil University, Creteil, France., Ljungman P; Deptartment of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Averbuch D; Faculty of Medicine, Hebrew University of Jerusalem, Pediatric Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel., Cesaro S; Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy., Baldomero H; EBMT Activity Survey Office, Hematology, Department of Medicine, University Hospital, Basel, Switzerland., Chabannon C; Institut Paoli Calmettes Comprehensive Cancer Center and Inserm CBT-1409, Centre d'Investigations Cliniques en Biothérapies, Marseille, France., Corbacioglu S; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany., Dolstra H; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Glass B; Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Greco R; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy., Kröger N; Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany., de Latour RP; BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France., Mohty M; Department of Hematology, Hospital Saint Antoine, Sorbonne University, INSERM UMRs938, Paris, France., Neven B; Pediatric Immune-Hematology Unit, Necker Children Hospital, Assistance Publique Hôpitaux de Paris, Paris, France., Peric Z; School of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain., Yakoub-Agha I; CHU de Lille, Université de Lille, INSERM U1286, Infinite, Lille, France., de la Camara R; Hematology Department, Hospital de la Princesa, Madrid, Spain.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2023 Aug; Vol. 58 (8), pp. 881-892. Date of Electronic Publication: 2023 May 06.
DOI: 10.1038/s41409-023-01998-2
Abstrakt: We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study). Results were compared to those in the ALL/AML/CML COD-1 study. Mortality from bacterial, viral, fungal, and parasitic infections decreased in very early, early and intermediate phases. In the late phase, mortality from bacterial infections increased, while mortality from fungal, viral, or unknown infectious etiology did not change. This pattern was similar for allo- and auto-HCT in COD-1 and COD-2 studies, with a distinct and constant lower incidence of all types of infections at all phases, after auto-HCT. In conclusion, infections were the main cause of death before day +100, followed by relapse. Mortality from infectious deaths significantly decreased, except late phase. Post-transplant mortality has significantly decreased in all phases, from all causes after auto-HCT; it has decreased in all phases after allo-HCT except late phase.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: